2,479 reports of this reaction
3.0% of all DARBEPOETIN ALFA reports
#3 most reported adverse reaction
OFF LABEL USE is the #3 most commonly reported adverse reaction for DARBEPOETIN ALFA, manufactured by Amgen, Inc. There are 2,479 FDA adverse event reports linking DARBEPOETIN ALFA to OFF LABEL USE. This represents approximately 3.0% of all 81,618 adverse event reports for this drug.
Patients taking DARBEPOETIN ALFA who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is a less commonly reported adverse event for DARBEPOETIN ALFA, but still significant enough to appear in the safety profile.
In addition to off label use, the following adverse reactions have been reported for DARBEPOETIN ALFA:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 2,479 FDA reports for DARBEPOETIN ALFA. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 3.0% of all adverse event reports for DARBEPOETIN ALFA, making it one of the most commonly reported side effect.
If you experience off label use while taking DARBEPOETIN ALFA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.